d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study

N. G. Cascella, F. Macciardi, C. Cavallini, E. Smeraldi

Research output: Contribution to journalArticle

Abstract

D-cycloserine, a partial agonist at the strichnine-insensitive glycine site of the NMDA receptor complex, was tested as adjuvant treatment to conventional neuroleptics in chronic schizophrenic volunteers. The drug was administered, o.a.d., at the daily dose of 250 mg for six weeks. Mental status outcome measures were completed at the end of each week of treatment. The major finding was a deteriora of the patients' clinical condition, specifically of their psychotic symptoms. These preliminary results are discussed among others in view of d-cycloserine pharmacologic properties and recent findings on the interaction between NMDA agonists and dopamine system. This study, finally, suggests the need for a controlled dose-finding trial to establish the activity and a therapeutic "window" of this drug in schizophrenia.

Original languageEnglish
Pages (from-to)105-111
Number of pages7
JournalJournal of Neural Transmission
Volume95
Issue number2
DOIs
Publication statusPublished - Jun 1994

Fingerprint

Cycloserine
Antipsychotic Agents
Schizophrenia
Dopamine Agonists
N-Methylaspartate
N-Methyl-D-Aspartate Receptors
Pharmaceutical Preparations
Glycine
Volunteers
Therapeutics
Outcome Assessment (Health Care)

Keywords

  • cycloserine
  • glycine
  • NMDA receptor
  • PCP-psychosis
  • schizophrenia

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia : an open-label study. / Cascella, N. G.; Macciardi, F.; Cavallini, C.; Smeraldi, E.

In: Journal of Neural Transmission, Vol. 95, No. 2, 06.1994, p. 105-111.

Research output: Contribution to journalArticle

Cascella, N. G. ; Macciardi, F. ; Cavallini, C. ; Smeraldi, E. / d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia : an open-label study. In: Journal of Neural Transmission. 1994 ; Vol. 95, No. 2. pp. 105-111.
@article{8fc663a61d7f496d9b7175817aa80383,
title = "d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study",
abstract = "D-cycloserine, a partial agonist at the strichnine-insensitive glycine site of the NMDA receptor complex, was tested as adjuvant treatment to conventional neuroleptics in chronic schizophrenic volunteers. The drug was administered, o.a.d., at the daily dose of 250 mg for six weeks. Mental status outcome measures were completed at the end of each week of treatment. The major finding was a deteriora of the patients' clinical condition, specifically of their psychotic symptoms. These preliminary results are discussed among others in view of d-cycloserine pharmacologic properties and recent findings on the interaction between NMDA agonists and dopamine system. This study, finally, suggests the need for a controlled dose-finding trial to establish the activity and a therapeutic {"}window{"} of this drug in schizophrenia.",
keywords = "cycloserine, glycine, NMDA receptor, PCP-psychosis, schizophrenia",
author = "Cascella, {N. G.} and F. Macciardi and C. Cavallini and E. Smeraldi",
year = "1994",
month = "6",
doi = "10.1007/BF01276429",
language = "English",
volume = "95",
pages = "105--111",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer-Verlag Wien",
number = "2",

}

TY - JOUR

T1 - d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia

T2 - an open-label study

AU - Cascella, N. G.

AU - Macciardi, F.

AU - Cavallini, C.

AU - Smeraldi, E.

PY - 1994/6

Y1 - 1994/6

N2 - D-cycloserine, a partial agonist at the strichnine-insensitive glycine site of the NMDA receptor complex, was tested as adjuvant treatment to conventional neuroleptics in chronic schizophrenic volunteers. The drug was administered, o.a.d., at the daily dose of 250 mg for six weeks. Mental status outcome measures were completed at the end of each week of treatment. The major finding was a deteriora of the patients' clinical condition, specifically of their psychotic symptoms. These preliminary results are discussed among others in view of d-cycloserine pharmacologic properties and recent findings on the interaction between NMDA agonists and dopamine system. This study, finally, suggests the need for a controlled dose-finding trial to establish the activity and a therapeutic "window" of this drug in schizophrenia.

AB - D-cycloserine, a partial agonist at the strichnine-insensitive glycine site of the NMDA receptor complex, was tested as adjuvant treatment to conventional neuroleptics in chronic schizophrenic volunteers. The drug was administered, o.a.d., at the daily dose of 250 mg for six weeks. Mental status outcome measures were completed at the end of each week of treatment. The major finding was a deteriora of the patients' clinical condition, specifically of their psychotic symptoms. These preliminary results are discussed among others in view of d-cycloserine pharmacologic properties and recent findings on the interaction between NMDA agonists and dopamine system. This study, finally, suggests the need for a controlled dose-finding trial to establish the activity and a therapeutic "window" of this drug in schizophrenia.

KW - cycloserine

KW - glycine

KW - NMDA receptor

KW - PCP-psychosis

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0028174008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028174008&partnerID=8YFLogxK

U2 - 10.1007/BF01276429

DO - 10.1007/BF01276429

M3 - Article

C2 - 7865165

AN - SCOPUS:0028174008

VL - 95

SP - 105

EP - 111

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 2

ER -